Adult; Aged; Aged, 80 and over; Anti-Bacterial Agents/pharmacology/therapeutic use; Carrier State/epidemiology/microbiology; Cross-Over Studies; Drug Resistance, Bacterial; Drug Therapy/methods; Europe/epidemiology; Female; Gram-Negative Bacteria/drug effects/isolation & purification; Gram-Negative Bacterial Infections/drug therapy/epidemiology/microbiology; Humans; Intensive Care Units; Male; Middle Aged; Prevalence
Abstract :
[en] BACKGROUND: Whether antibiotic rotation strategies reduce prevalence of antibiotic-resistant, Gram-negative bacteria in intensive care units (ICUs) has not been accurately established. We aimed to assess whether cycling of antibiotics compared with a mixing strategy (changing antibiotic to an alternative class for each consecutive patient) would reduce the prevalence of antibiotic-resistant, Gram-negative bacteria in European intensive care units (ICUs). METHODS: In a cluster-randomised crossover study, we randomly assigned ICUs to use one of three antibiotic groups (third-generation or fourth-generation cephalosporins, piperacillin-tazobactam, and carbapenems) as preferred empirical treatment during 6-week periods (cycling) or to change preference after every consecutively treated patient (mixing). Computer-based randomisation of intervention and rotated antibiotic sequence was done centrally. Cycling or mixing was applied for 9 months; then, following a washout period, the alternative strategy was implemented. We defined antibiotic-resistant, Gram-negative bacteria as Enterobacteriaceae with extended-spectrum beta-lactamase production or piperacillin-tazobactam resistance, and Acinetobacter spp and Pseudomonas aeruginosa with piperacillin-tazobactam or carbapenem resistance. Data were collected for all admissions during the study. The primary endpoint was average, unit-wide, monthly point prevalence of antibiotic-resistant, Gram-negative bacteria in respiratory and perineal swabs with adjustment for potential confounders. This trial is registered with ClinicalTrials.gov, number NCT01293071. FINDINGS: Eight ICUs (from Belgium, France, Germany, Portugal, and Slovenia) were randomly assigned and patients enrolled from June 27, 2011, to Feb 16, 2014. 4069 patients were admitted during the cycling periods in total and 4707 were admitted during the mixing periods. Of these, 745 patients during cycling and 853 patients during mixing were present during the monthly point-prevalence surveys, and were included in the main analysis. Mean prevalence of the composite primary endpoint was 23% (168/745) during cycling and 22% (184/853) during mixing (p=0.64), yielding an adjusted incidence rate ratio during mixing of 1.039 (95% CI 0.837-1.291; p=0.73). There was no difference in all-cause in-ICU mortality between intervention periods. INTERPRETATION: Antibiotic cycling does not reduce the prevalence of carriage of antibiotic-resistant, Gram-negative bacteria in patients admitted to the ICU. FUNDING: European Union Seventh Framework Programme.
Vincent, JL, Rello, J, Marshall, J, et al. International study of the prevalence and outcomes of infection in intensive care units. JAMA 302 (2009), 2323–2329.
WHO. Antimicrobial resistance: global report on surveillance 2014. 2014, World Health Organization, Geneva.
Derde, LP, Cooper, BS, Goossens, H, et al. Interventions to reduce colonisation and transmission of antimicrobial-resistant bacteria in intensive care units: an interrupted time series study and cluster randomised trial. Lancet Infect Dis 14 (2014), 31–39.
Huang, SS, Septimus, E, Hayden, MK, et al. Effect of body surface decolonisation on bacteriuria and candiduria in intensive care units: an analysis of a cluster-randomised trial. Lancet Infect Dis 16 (2016), 70–79.
Harris, AD, Pineles, L, Belton, B, et al. Universal glove and gown use and acquisition of antibiotic-resistant bacteria in the ICU: a randomized trial. JAMA 310 (2013), 1571–1580.
Ong, DS, Jongerden, IP, Buiting, AG, et al. Antibiotic exposure and resistance development in Pseudomonas aeruginosa and Enterobacter species in intensive care units. Crit Care Med 39 (2011), 2458–2463.
Noteboom, Y, Ong, DS, Oostdijk, EA, et al. Antibiotic-induced within-host resistance development of Gram-negative bacteria in patients receiving selective decontamination or standard care. Crit Care Med 43 (2015), 2582–2588.
Gerding, DN, Larson, TA, Aminoglycoside resistance in Gram-negative bacilli during increased amikacin use. Comparison of experience in 14 United States hospitals with experience in the Minneapolis Veterans Administration Medical Center. Am J Med 79 (1985), 1–7.
Livermore, DM, Of stewardship, motherhood and apple pie. Int J Antimicrob Agents 43 (2014), 319–322.
Bonhoeffer, S, Lipsitch, M, Levin, BR, Evaluating treatment protocols to prevent antibiotic resistance. Proc Natl Acad Sci USA 94 (1997), 12106–12111.
Gerding, D, Larson, T, Hughes, R, Weiler, M, Shanholtzer, C, Peterson, LR, Aminoglycoside resistance and aminoglycoside usage: ten years of experience in one hospital. Antimicrob Agents Chemother, 35, 1991, 1284.
van Duijn, PJ, Bonten, MJ, Antibiotic rotation strategies to reduce antimicrobial resistance in Gram-negative bacteria in European intensive care units: study protocol for a cluster-randomized crossover controlled trial. Trials, 15, 2014, 277.
Cobos-Trigueros, N, Sole, M, Castro, P, et al. Acquisition of Pseudomonas aeruginosa and its resistance phenotypes in critically ill medical patients: role of colonization pressure and antibiotic exposure. Crit Care, 19, 2015, 218.
Nijssen, S, Bootsma, M, Bonten, M, Potential confounding in evaluating infection-control interventions in hospital settings: changing antibiotic prescription. Clin Infect Dis 43 (2006), 616–623.
Barlam, TE, Cosgrove, SE, Abbo, LM, et al. Implementing an antibiotic stewardship program: guidelines by the Infection Diseases Society of America and the Society for Healthcare Epidemiology of America. Clin Infect Dis 62 (2016), 351–377.
de With, K, Allerberger, F, Amann, S, et al. Strategies to enhance rational use of antibiotics in hospital: a guideline by the German Society for Infectious Diseases. Infection 44 (2016), 395–439.
Vincent, JL, Moreno, R, Clinical review: scoring systems in the critically ill. Crit Care, 14, 2010, 207.
WHO. Hand hygiene technical reference manual. http://apps.who.int/iris/bitstream/10665/44196/1/9789241598606_eng.pdf, 2009 (accessed Jan 2, 2018).
Bonten, MJ, Slaughter, S, Ambergen, AW, et al. The role of “colonization pressure” in the spread of vancomycin-resistant enterococci: an important infection control variable. Arch Intern Med 158 (1998), 1127–1132.
Beardmore, RE, Peña-Miller, R, Gori, F, Iredell, J, Antibiotic cycling and antibiotic mixing: which one best mitigates antibiotic resistance?. Mol Biol Evol 34 (2017), 802–817.
Kouyos, R, Abel zur Wiesch, P, Bonhoeffer, S, Informed switching strongly decreases the prevalence of antibiotic resistance in hospital wards. PLoS Comput Biol, 7, 2011, e1001094.
de Smet, AM, Kluytmans, JA, Cooper, BS, et al. Decontamination of the digestive tract and oropharynx in ICU patients. N Engl J Med 360 (2009), 20–31.
Oostdijk, EA, Kesecioglu, J, Schultz, MJ, et al. Effects of decontamination of the oropharynx and intestinal tract on antibiotic resistance in ICUs: a randomized clinical trial. JAMA 312 (2014), 1429–1437.
Fagon, JY, Chastre, J, Wolff, M, et al. Invasive and noninvasive strategies for management of suspected ventilator-associated pneumonia: a randomized trial. Ann Intern Med 132 (2000), 621–630.
de Jong, E, van Oers, JA, Beishuizen, A, et al. Efficacy and safety of procalcitonin guidance in reducing the duration of antibiotic treatment in critically ill patients: a randomised, controlled, open-label trial. Lancet Infect Dis 16 (2016), 819–827.
Bouadma, L, Luyt, CE, Tubach, F, et al. Use of procalcitonin to reduce patients' exposure to antibiotics in intensive care units (PRORATA trial): a multicentre randomised controlled trial. Lancet 375 (2010), 463–474.